

CURRICULUM VITAE

Dr. med. Lorenzo Magenta

DATI PERSONALI

Data di nascita 09.03.1964
Nazionalità: doppia cittadinanza svizzera e italiana
Stato civile sposato, 2 figli

FORMAZIONE

07.1984 Maturità classica presso Liceo Classico A. Volta di Como, IT
05.10.1995 Laurea in Medicina e Chirurgia presso Università Statale di Milano, IT
Tesi di laurea: "Immunità cellulo-mediata nella miocardite chagastica cronica. Caratterizzazione fenotipica degli infiltrati infiammatori in venti casi autoptici."
Relatore: Prof. A. Lazzarin, Votazione 110/110
30.11.1995 Abilitazione all'esercizio della professione di Medico-Chirurgo, IT
13.11.2000 Specializzazione in Medicina Tropicale all'Università degli Studi di Milano, IT
11.08.2008 Riconoscimento federale del diploma di medico
14.08.2008 Riconoscimento federale quale Medico specialista in Medicina tropicale e medicina di viaggio
11.02.2009 Autorizzazione al libero esercizio nel Canton Ticino
02.04.2012 Titolo federale di perfezionamento di Medico Generico

ESPERIENZE ED ATTIVITÀ PROFESSIONALI

11.1996 - 11.2000 • Medico specializzando in medicina tropicale, Divisione di Malattie Infettive, Ospedale San Raffaele, Milano
01.2001 - 03.2005 • Medico consulente, divisione di Malattie Infettive, Ospedale San Raffaele, Milano
11.1996 - 08.2010 • Medico assistente scientifico, Servizio di Malattie Infettive, Ospedale Regionale di Lugano, Lugano
09.2010 - 07.2013 • Medico ospedaliero, Centro di Epatologia, Clinica Luganese, Lugano
07.2013 -01-2021 • Medico consulente, Ospedale La Carità, EOC, Locarno

07.2013 – ad oggi • Vicedirettore, Epatocentro Ticino, Lugano
01.2015 – ad oggi • Medico consulente, Clinica Luganese Moncucco, Lugano

PRINCIPALI AREE DI ESPERIENZA E INTERESSE

- Esperienza di lunga data nel trattamento di pazienti con dipendenze (alcol e sostanze stupefacenti) nell'ambito delle principali patologie correlate (malattie infettive ed epatopatie)
- Gestione pazienti con infezione da HIV e relative complicanze
- Gestione pazienti con epatiti virali
- Gestione pazienti con cirrosi epatica ed end-stage liver disease
- Gestione pazienti trapiantati di fegato
- Gestione pazienti affetti da obesità, con malattia da fegato grasso (NAFLD) o steatoepatite non alcolica (NASH)
- Gestione casi epatologici complessi (epatopatie colestatiche, metaboliche o autoimmuni)
- Gestione pazienti con tumori del fegato e delle vie biliari
- Dal 1996 sub-investigatore o principale investigatore in circa 70 protocolli di ricerca clinica nel campo della terapia antiretrovirale dell'infezione da HIV, della terapia dell'epatite C e della terapia della NASH

ASSOCIAZIONI PROFESSIONALI

- Federazione dei Medici Svizzeri (FMH)
- Ordine dei Medici del Canton Ticino (OMCT)
- Circolo Medico di Lugano (CML)
- Società Svizzera di Malattie Infettive (SSI)
- Società Svizzera di Medicina Tropicale e Parassitologia (SSTMP)
- Swiss Association for the Study of the Liver (SASL)

LINGUE

- Italiano (lingua madre)
- Inglese (buone conoscenze)
- Francese (conoscenze di base della lingua scritta)

INTERESSI PERSONALI

- Lettura
- Viaggi
- Fotografia
- Sport: sci alpino, sci da fondo, escursionismo e passione per ricerca funghi

PUBBLICAZIONI

- B. Müllhaupt, D. Semela, L. Ruckstuhl, **L. Magenta**, O. Clerc, R. Torgler, F. Negro, N. Semmo. Real-world effectiveness and safety of glecaprevir/pibrentasvir therapy in patients with chronic hepatitis C virus infection in Switzerland. *Swiss Med Wkly.* 2021;151:w20399
- N. Semmo, B. Müllhaupt, L. Ruckstuhl, **L. Magenta**, O. Clerc, R. Torgler, D. Semela. A prospective, multicenter, post-marketing observational study to measure the quality of life of HCV genotype 1 infected, treatment naïve patients suffering from fatigue and receiving 3D regimen: The HEMATITE study. *Plos One* November 4, 2020. <https://doi.org/10.1371/journal.pone.0241267>
- A. De Gottardi, C. Fratila, R. Bertoli, A. Cerny, **L. Magenta**, P. Gianella, P. Majno-Hurst, A. Ceschi, G. Vanini, E. Bernasconi. Clinical characteristics and management of a liver transplanted patient admitted with SARS-CoV-2 infection. *Clin Res Hepatol Gastroenterol* 2020 Jun 10;S2210-7401(20)30159-5. doi: 10.1016/j.clinre.2020.05.014.
- J. Bachofner, P.V. Valli, I. Bergamin, A. Kröger, P. Künzler, A. Baserga, D.L. Braun, B. Seifert, A. Moncsek, J. Fehr, D. Semela, **L. Magenta**, B. Müllhaupt, B. Terziroli Beretta-Piccoli, J. Mertens. The Swiss Hepatitis C Cohort Study. Excellent outcome of Direct Acting Antiviral treatment for chronic hepatitis C in Switzerland. *Swiss Med Wkly.* 2018 Jan 29;148:w14560. doi: 10.4414/smw.2018.14560. eCollection 2018 Jan 29.
- D. Semela, U. Rusch, P. Künzler, J. Mertens, B. Müllhaupt, M. Heim, N. Semmo, G. Stirnimann, J.F. Dufour, A. Baserga, **L. Magenta**, F. Negro, P. Bruggmann. Increasing imports of Direct-Acting Antivirals (DAAs) via FixHepC Buyers Club and medical tourism by Swiss patients with chronic hepatitis C infection. *Swiss Med Wkly.* 2017 ; 147 (Suppl 225)
- J.A. Bachofner, P.V. Valli, A. Kröger, I. Bergamini, P. Künzler, A. Baserga, D. Braun, B. Seifert, A. Moncsek, J. Fehr, D. Semela, **L. Magenta**, B. Müllhaupt, B. Terziroli Beretta-Piccoli, J.C. Mertens. Direct antiviral agent treatment of chronic hepatitis C results in rapid regression of transient elastography and fibrosis markers fibrosis-4 score and aspartate aminotransferase-platelet ratio index. *Liver Int.* 2107; 37:369-376
- A. De Gottardi, J. Trebicka, C. Klinger, A. Plessier, S. Seijo, B. Terziroli, **L. Magenta**, D. Semela, E. Buscarini, P. Langlet, J. Görtzen, A. Puente, B. Müllhaupt, C. Navascuès, F. Nery, P. Deltenre, F. Turon, C. Engelmann, R. Arya, K. Caca, M. Peck-Radosavljevic, FWG. Leebeek, D. Valla, J.C. Garcia-Pagan; VALDIG Investigators. Antithrombotic treatment with direct-acting oral anticoagulants in patients with splanchnic vein thrombosis and cirrhosis. *Liver Int.* 2017 May;37(5):694-699. doi: 10.1111/liv.13285.
- A. De Gottardi, S. Seijo, A. Plessier, J. Schouten, J. Trebicka, B. Terziroli, **L. Magenta**, D. Semela, P. Langlet, F. Turon, R. Arya, M. Peck-Radosavljevic, D. Valla, J.C. Garcia-Pagan O077 : Use of direct oral anticoagulants (DOACs) in patients with splanchnic vein thrombosis and/or cirrhosis. *J Hepatol.*2015; 62, suppl 2: S229
- L. Andreocchi, V. Toma, A. Canonica-Lepori, **L. Magenta**, S. Gyorik, L. Pellegrini, E. Bernasconi. Telaprevir-induced renal impairment: three clinical cases and a review of the literature. *Infect Dis (Lond).* 2015 Sep;47(9):662-7
- **L. Magenta**, R. Monotti. Epatite C. *Tribuna Medica Ticinese.* Maggio 2015;5: 119-125.
- **L. Magenta**. HIV: complicanze a lungo termine. *Tribuna Medica Ticinese.* Novembre 2012;11: 397-402.
- H.C. Bucher, W. Richter, T.R. Glass, **L. Magenta**, Q. Wang, M. Cavassini, P. Vernazza, B. Hirschel, R. Weber, H. Furrer, M. Battegay, E. Bernasconi. Small Dense Lipoproteins, Apolipoprotein B, and Risk of Coronary Events in HIV-Infected Patients on Antiretroviral Therapy: The Swiss HIV Cohort Study. *J Acquir Immune Defic Syndr.* 2012 June 1;60(2):135-142.
- **L. Magenta**, S. Dell-Kuster, W.O. Richter, J. Young, R. Weber, M. Flepp, B. Hirschel, P. Vernazza, H. Furrer, M. Cavassini, L.A. Decosterd, H. Bucher, E. Bernasconi, and the Swiss HIV Cohort Study. Lipid and lipoprotein profile in HIV-infected patients treated with

- lopinavir/ritonavir as a component of the first combination antiretroviral therapy. *AIDS Res Hum Retroviruses*. 2011 May;27(5):525-33
- N.J. Mueller, C.A. Fux, B. Ledergerber, L. Elzi, P. Schmid, T. Dang, **L. Magenta**, A. Calmy, A. Vergopoulos, H.A. Bischoff-Ferrari, and the Swiss HIV Cohort Study. High prevalence of severe vitamin D deficiency in cART naïve and successfully treated Swiss HIV patients. *AIDS*, 2010 May 15;24(8):1127-34.
- **L. Magenta**, C. Gandola, G. Robotti, C. Tosi, M. Gerbino, F. Scacchi, E. Bernasconi. Intramedullary spinal cryptococcoma in a patient with AIDS: case report and review of literature. *Shelter*, Nov 2005; issue 1: 40-47.
- **L. Magenta**, W.O. Richter, M. Opravil, M. Flepp, H. Drechsler, P. Schmid, J.M. Evison, B. Bernasconi, E. Bernasconi. Lipoprotein pattern in HIV infected patients before starting antiretroviral therapy with lopinavir/ritonavir. *European Journal of Medical Research*, 2005 October 21, 10 (Suppl III): 5-6.
- J.P. Zuber, A. Calmy, J.M. Evison, B. Hasse, V. Schiffer, T. Wagels, R. Nuesch, **L. Magenta**, B. Lederberger, R. Jenni, R. Speich, M. Opravil. Pulmonary arterial hypertension related to HIV infection: improved hemodynamics and survival associated with antiretroviral therapy. *Clinical Infectious Diseases*, 2004 April 15; 38: 1178-85.
- E. Bernasconi, M. Uhr, **L. Magenta**, A. Ranno, A. Telenti and the Swiss HIV Cohort Study. Homocysteinaemia in HIV-infected patients treated with highly active antiretroviral therapy. *AIDS*, 2001 May 25; 15(8): 1081-2.
- G. Tambussi, S. Ghezzi, S. Nozza, G. Vallanti, **L. Magenta** et al. Efficacy of low-dose intermittent subcutaneous interleukin (IL)-2 in antiviral drug-experienced human immunodeficiency virus-infected persons with detectable virus load: a controlled study of 3 IL-2 regimens with antiviral drug therapy. *J Infect Dis*. 2001 May 15; 183(10): 1476-84.
- E. Bernasconi, **L. Magenta**, J.C. Piffaretti, A. Carota, T. Moccetti. Are nelfinavir-containing regimens effective as second-line triple therapy? *AIDS*, 2000 Jan 7; 14(1): 95-6.
- **L. Magenta**, M. Moro, M. Guffanti, C. Uberti Foppa, M.A. Cardoso de Almeida, M. Sadigursky, A. Lazzarin, C.L. Parravicini, G. Gaiera. Ruolo dei T linfociti CD4+ e CD8+ nell'evoluzione degli infiltrati intramiocardici nella miocardiopatia chagastica cronica. *Italian Journal of Tropical medicine*, 09.05.1998.

ABSTRACTS

- N. Semmo, B.Müllhaupt, L. Ruckstuhl, **L. Magenta**, O. Clerc, R. Torgler, D. Semela. Quality of life measurement using wrist actigraphy in HCV genotype 1 infected, treatment naïve patients suffering from fatigue and receiving ombitasvir, paritaprevir and ritonavir tablets and dasabuvir tablets (Viekirax/Exviera; 3D regimen). *EASL International Liver Congress (10-14 aprile 2019, Vienna)*
- A. Aghemo, S. Bourgeois, M. Gschwantler, Y. Sanchez, L. Larsen, M. Bondin, **L. Magenta**, T. Asselah. Real-world health care resource utilization and quality of life with G/P treatment: a pooled analysis from post-marketing observational studies. *EASL International Liver Congress (10-14 aprile 2019, Vienna)*
- A. Aghemo, S. Bourgeois, M. Bondin, C. De Alvaro, **L. Magenta**, J. Foucher, S. Sonparote, Z.Z. Zhang, M. Gschwantler. Impact of Comorbidities and Co-medications on the Effectiveness and Safety of Glecaprevir Plus Pibrentasvir in Clinical Practice: Real-World Evidence from a Pooled Analysis of Postmarketing Observational Studies. *AASLD Liver meeting 2018 (9-13 novembre 2018, San Francisco)*
- D. Semela, U. Rusch, P. Künzler, J. Mertens, B. Müllhaupt, M. Heim, N. Semmo, G. Stirnimann, J.F. Dufour, A. Baserga, **L. Magenta**, F. Negro, P. Bruggmann. Increasing imports of Direct-Acting Antivirals (DAAs) via FixHepC Buyers Club and medical tourism by Swiss patients with chronic hepatitis C infection. *SASL, SSG Annual Meeting, Lausanne, 14-15 Sep 2017*
- J.A. Bachofner, P.V. Valli, A. Kroeger, I. Bergamin, P. Kuenzler, A. Baserga, D. Braun, B. Seifert, A. Moncsek, J. Fehr, D. Semela, **L. Magenta** et al. Real life experience with direct

-
- antiviral agent (DAA) treatment of chronic HCV infection in three Swiss centers. Annual meeting of the Swiss Society of Gastroenterology (SGG), Interlaken, 22-23 September 2016
- J.A. Bachofner, P.V. Valli, A. Kroeger, I. Bergamin, P. Kuenzler, A. Baserga, D. Braun, B. Seifert, A. Moncsek, J. Fehr, D. Semela, **L. Magenta** et al. DAA treatment of chronic hepatitis C results in rapid regression of transient elastography and fibrosis markers FIB-4 and APRI. Annual meeting of the Swiss Society of Gastroenterology (SGG), Interlaken, 22-23 September 2016
- A. Moriggia, M. Balmelli, A. Baserga, V. Gurtner, D. Hagara, **L. Magenta** et al. Hepatitis C treatment on PWUD in the DAA's era: high rate of virological response in the real life. 5th International Symposium on Hepatitis Care in Substance Users (INHSU), Oslo, 7-9 September 2016
- A. Moriggia, **L. Magenta** et al. High prevalence of liver fibrosis among people attending addiction clinics and rehabilitation facilities in southern Switzerland: results of two different screening programs for liver disease. 5th International Symposium on Hepatitis Care in Substance Users (INHSU), Oslo, 7-9 September 2016
- J.J. Feld, O. Weiland, R.T. Marinho, H. Wedemeyer, I.M. Jacobson, D.M. Jensen, T. Hassanein, V. De Ledinghen, M. Diago, **L. Magenta**, R.J. De Knecht, J.J. Xiong, E. Coakley, T. Baykal, F. Tatsch, G.R. Foster. ABT-450/r/Ombitasvir and Dasabuvir with Ribavirin Achieves High Sustained Virologic Response Rates Regardless of Baseline Characteristics: Pooled Analyses of the SAPPHIRE-I and SAPPHIRE-II Studies. IDWeek 2014 Meeting of the Infectious Diseases Society of America
- S.D. Shafran, S. Roberts, D. Crawford, V. de Ledinghen, S.D. Ryder, **L. Magenta** et al. SAPPHIRE-I Subpopulation Analysis: ABT-450/r/Ombitasvir (ABT-267), Dasabuvir (ABT-333), and Ribavirin Regimen Achieves High Sustained Virologic Response Rates 12 Weeks Post-treatment in Treatment-naïve Patients With Chronic HCV GT 1 Infection, Regardless of Baseline Characteristics; Oral Abstract Session; 20th International AIDS Conference, Melbourne (Australia), July 20-25, 2014
- J.J. Feld, O. Weiland, R.T. Marinho, H. Wedemeyer, I.M. Jacobson, D.M. Jensen, T. Hassanein, V. De Ledinghen, M. Diago, **L. Magenta**, et al. ABT-450/R/Ombitasvir and dasabuvir with ribavirin achieves high sustained virologic response rates regardless of baseline characteristics: pooled analyses of the Sapphire-I and Sapphire-II studies; Oral abstract session; ID week, Philadelphia (USA), 8-12 October 2014
- **L. Magenta**, E. Fossati, B. Terziroli, V. Gurtner, A. Cerny. Results of an educational and screening program for liver diseases in patients attending substance use rehabilitation programs in southern Switzerland; Second international Symposium on Hepatitis Care in Substance Users, Bruxelles 15-16 September 2011
- **L. Magenta**, A. Cerny, P. Antonini. Community acquired staphylococcus caprae endocarditis: case report and review of the literature. Abstract at the Reunion Annuelle Commune Societè Suisse d'Infectiologie, Societè Suisse de Medicine Tropicale et de Medicine des Voyages, Interlaken 24-25 August 2011
- **L. Magenta**, W.O. Richter, M. Opravil, M. Flepp, O. Keiser, H. Bucher, H. Drechsler, P. Schmid, J.M. Evison, M. Cavassini, B. Bernasconi, E. Bernasconi. Triglycerides and small, dense low-density lipoprotein in HIV infected patients treated with lopinavir/ritonavir as a component of the first combination antiretroviral therapy. Abstract n°134; Eighth International Congress on Drug Therapy in HIV Infection, Glasgow 12-16 November 2006.
- E. Bernasconi, **L. Magenta**, P. Vernazza, C. Bellini, P. Schmid, B. Miazza, J.C. Piffaretti, A. Cerny. Interferon alfa-2a and ribavirin "low dose" for the treatment of HCV infection in HIV co-infected patients. An open-label, pilot study. Abstract n° WB6037 XIV International AIDS Conference, Barcellona 7-12 July 2002.
- B. Hirschel, C. Fagard, M. Le Braz, H. Guentard, H. Hirsch, T. Wagels, **L. Magenta** et al. Granulocyte macrophage colony stimulating factor (GM-CSF) during structured treatment interruptions. Abstract n° B10470; XIV International AIDS Conference, Barcellona 7-12 July 2002.

-
- M. Cernuschi, B. Giudici, A. Tosoni, **L. Magenta** et al. Chronic diarrhea in HIV-positive patients: ultrastructural study of duodenal mucosa. Abstract n° 162; Ninth International Congress on Infectious Diseases, Buenos Aires, Argentina, April 10-13, 2000.
- M. Maillard, C. Uberti-Foppa, N. Gianotti, M. Cernuschi, G. Fusetti, **L. Magenta** et al. Increase invasive Aspergillosis among human immunodeficiency virus (HIV) infected patients. Abstract n°626; Seventh European Conference on Clinical Aspects and Treatment of HIV-infection, Lisbon, October 23-27, 1999.
- A. Bernasconi, F. Pelloni, **L. Magenta** et al. Bowen's disease: an emerging pathology related to HIV-infection? Abstract n°684; Seventh European Conference on Clinical Aspects and Treatment of HIV-infection, Lisbon, October 23-27, 1999.
- E. Bernasconi, M. Uhr, M. Telenti, A. Bernasconi, **L. Magenta** et al. Homocysteinemia in HIV-1 infected patients treated with HAART. Abstract n°806; Seventh European Conference on Clinical Aspects and Treatment of HIV-infection, Lisbon, October 23-27, 1999.
- E. Bernasconi, **L. Magenta**, J.C. Piffaretti et al. Are nelfinavir containing regimens effective as second line triple therapy? Abstract n° 22381; 12th World AIDS Conference, Geneva, June28-July 3 1998.
- E. Bernasconi, A. Carota, **L. Magenta** et al. Metabolic changes in HIV-infected patients treated with protease inhibitors. Abstract n°178*/12375; 12th World AIDS Conference, Geneva, June28-July 3 1998.
- **L. Magenta**, M. Moro, M. Guffanti, C. Uberti Foppa, M.A. Cardoso de Almeida, M. Sadigursky, A. Lazzarin, C. Parravicini, G. Gaiera. Ruolo di T linfociti CD4+ e CD8+ nell'evoluzione degli infiltrati infiammatori intramiocardici nella miocardiopatia chagastica cronica. Italian Journal of Tropical Medicine; Atti 2° Congresso Nazionale della Società Italiana di medicina Tropicale, 7-9 May 1998, Bardolino.
- L. Fumagalli, M.G. Viganò, R. Turconi, H. Hasson, **L. Magenta** et al. Impact on disease progression and survival of combined triple antiretroviral therapy and chemotherapy in HIV-positive patients with pulmonary Kaposi's sarcoma. Abstract n° 555; Sixth European Conference on Clinical Aspects and Treatment of HIV-Infection, Hamburg, October 11-15, 1997.

Lugano, 28.08.2021